PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
I urge you and your administration to work in partnership with California and the other eight states that have legalized recreational marijuana for adult use in a way that will let us enforce our state laws that protect the public and our children while targeting the bad actors." Newsom responded to comments by Spicer that compared cannabis to opioids: "Unlike marijuana, opioids represent an addictive and harmful substance, and I would welcome your administration's focused efforts on tackling this particular public health crisis."
The Horizontal Working Party on Drugs (better known as Horizontal Drug Group or HDG) is a Council Working Party, a preparatory body of the Council of the European Union established in 1997, responsible for the lead and management of the work of the council and of the European Union (EU) on drug policy. The HDG meets monthly in Brussels's Europa building or in the Justus Lipsius building, and prepares all relevant legislation and political documents to be adopted by EU's Committee of Permanent Representatives (COREPER II) and subsequently by the Council, such as EU drugs strategies, action plans on drugs, and statements on drug-related aspects to be presented at international fora like the United Nations Commission on Narcotic Drugs. Since 2018, the HDG is also responsible to establish the imperative mandate for the vote on international scheduling by member state of the EU at the Commission on Narcotic Drugs. The HDG engages and closely collaborates with other EU institutions like the European Monitoring Centre for Drugs and Drug Addiction and Europol. There are frequent meetings of EU countries' national drugs coordinators held as part of HDG meetings. In addition, the HDG regularly meets with delegates from other regions and third countries within the EU's area of interest (Russia, Turkey, the Western Balkans, the United States within a so-called "Transatlantic Dialogue", Western Africa, Andes Community, and with countries from Latin America and the Caribbean within the "Technical Committee EU/LAC").
=== Functions of macrophytes in aquatic systems === Macrophytes perform many ecosystem functions in aquatic ecosystems and provide services to human society. One of the important functions performed by macrophyte is uptake of dissolved nutrients including nitrogen and phosphorus. Macrophytes are widely used in constructed wetlands around the world to remove excess N and P from polluted water. Besides direct nutrient uptake, macrophytes indirectly influence nutrient cycling; especially N cycling through influencing the denitrifying bacterial functional groups that are inhabiting on roots and shoots of macrophytes. Macrophytes promote the sedimentation of suspended solids by reducing the current velocities, impede erosion by stabilising soil surfaces. Macrophytes also provide spatial heterogeneity in otherwise unstructured water column. Habitat complexity provided by macrophytes tends to increase diversity and density of both fish and invertebrates. The additional site-specific macrophytes' value provides wildlife habitat and makes treatment systems of wastewater aesthetically satisfactory.
In late 1991, Fripp asked former Japan singer David Sylvian to join a new King Crimson line-up. Sylvian declined the offer, but agreed to work with Fripp on a collaborative album; the resulting album The First Day was issued in 1993 under the name Sylvian/Fripp. In June 1993, Fripp began to assemble a larger version of King Crimson featuring Belew and Levin, Chapman Stick player Trey Gunn (a veteran of Fripp's Guitar Craft courses and a session musician on The First Day) and drummer Jerry Marotta, with whom Fripp and Levin had played in Peter Gabriel's band. After Sylvian/Fripp's closing concerts at the Royal Albert Hall in December 1993, Fripp decided to ask the tour's drummer Pat Mastelotto, formerly of Mr. Mister, to join instead of Marotta. Bruford would become the last member of the 1980s quartet to return to the band. Bruford later said he had lobbied Fripp at the last minute because he believed that Crimson was still very much "his gig", and that Fripp had come up with a philosophical explanation for utilizing both Mastelotto and Bruford later. One of the conditions Fripp imposed upon Bruford if he were to return was to give up all creative control to Fripp. Fripp later explained that he had a vision of a "Double Trio" with two guitarists, two bassists, and two drummers while driving along the Chalke Valley in Wiltshire one afternoon in 1992. Following rehearsals in Woodstock, New York, the group released the EP Vrooom in October 1994.
Sources: en.wikipedia.org
The study Radiological Evaluation of Breasts Reconstructed with Lipo-modeling (2005) indicates that the therapeutic efficacy of fat-graft breast reconstruction in the treatment of radiation therapy damage to the chest, the incidental reduction of capsular contracture, and the improved coverage of the breast implants. In fat-graft breast augmentation procedures, there is the risk that the adipocyte tissue can become necrotic, undergo metastatic calcification, develop cysts, and agglomerate into palpable lumps. Although the cause of metastatic calcification is unknown, the post-procedure biological changes occurred to the fat-graft tissue resemble the tissue changes usual to breast surgery procedures, such as reduction mammoplasty. The pre-procedure mammograms were negative for the presence of the malignant neoplasms of breast cancer. In the 17-patient cohort, two women developed breast cancer after the breast augmentation: one woman at 12 months and the second woman at 92 months. Further, the study Cell-assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells (2007), in a 40-woman cohort, the inclusion of adipose stem cells in the grafts of adipocyte fat increased the rate of the corrective success of the autologous fat-grafting procedure.
=== Hematopoietic stem cell transplantation === Hematopoietic stem cell transplantation (HSCT) involves replacing the dysfunctional stem cells from a person with sickle cell disease with healthy cells from a well-matched donor. Finding a well matched donor is essential to the process' success. Different types of donors may be suitable, including umbilical cord blood, human leukocyte antigen (HLA) matched relatives, or HLA-matched donors who are not related to the person being treated. Risks associated with HSCT can include graft-versus-host disease, failure of the graft, and other toxicity related to the transplant.
Rosett (1953), dean of the University of Chicago Booth School of Business, Arts and Sciences at Washington University in St. Louis, and chairman of National Bureau of Economic Research Robert L. Friedheim (1955), former director of the USC School of International Relations Calvin B. T. Lee (1955), former chancellor of University of Maryland, Baltimore County and acting president of Boston University Robert E. Paaswell (1956), civil engineer, former interim president of City College of New York and CEO of Chicago Transit Authority Kenneth Gros Louis (1959), chancellor of Indiana University system Richard A. Merrill (1959), 7th dean of the University of Virginia School of Law Stephen Joel Trachtenberg (1959), president of the University of Hartford and of George Washington University David C. Levy (1960), dean of the Parsons School of Design and president of the Corcoran Gallery of Art Steven M. Cahn (1966), provost and acting president of Graduate Center of the City University of New York Dimitri B. Papadimitriou (1970), executive vice president and provost of Bard College David Rubin (1970), professor of communications and dean of S. I. Newhouse School of Public Communications Alan Cooper (1971), provost of Jewish Theological Seminary of America, former member of Sha Na Na William Germano (1972), dean of the faculty of humanities and social sciences at Cooper Union, former editor-in-chief of Columbia University Press Saul Levmore (1973), commercial law scholar, former dean of the University of Chicago Law School Ronald Mason Jr.
== Future research == Research in this field is progressing along several frontiers. First is the reductive program of understanding how bioelectric signals are produced, how voltage changes in the cell membrane are able to regulate cell behavior, and what the genetic and epigenetic downstream targets of bioelectric signals are. A few mechanisms that transduce bioelectric change into alterations of gene expression are already known, including the bioelectric control of movement of small second-messenger molecules through cells, including serotonin and butyrate, voltage sensitive phosphatases, among others. Also known are numerous gene targets of voltage signaling, such as Notch, BMP, FGF, and HIF-1α. Thus, the proximal mechanisms of bioelectric signaling within single cells are becoming well-understood, and advances in optogenetics and magnetogenetics continue to facilitate this research program. More challenging however is the integrative program of understanding how specific patterns of bioelectric dynamics help control the algorithms that accomplish large-scale pattern regulation (regeneration and development of complex anatomy). The incorporation of bioelectrics with chemical signaling in the emerging field of probing cell sensory perception and decision-making is an important frontier for future work. Bioelectric modulation has shown control over complex morphogenesis and remodeling, not merely setting individual cell identity.
=== Theft === To best establish protocols for specimen movement control, a system of documentation can be set up to monitor and control collections. At the National Museum of Natural History, theft is prevented by maintaining limited access to where collections are stored. In the event of a specimen leaving the site through outgoing loans, records are kept which gather letters of request, the transmission of names, and other supporting documentation.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.